Skip to content
DataLookout
Menu

NCT06992336

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 2 words
    • Interventions modified
    • Enrollment target: 411 to 430
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

iDFS
Timeframe: from randomization to any of the following events: local or distant relapse; contralateral breast caner, death of any cause,assessed up to 36 months.

Secondary (3)

dDFS
OS
ctDNA clearance

Arms and interventions

AExperimental

Apatinib 8mg qd PO,357days Camrelizumab 200mg i.v. Q3W or immunotherapy continued as in the NAC(17cycles in total). Capecitabine 1000 or 1250 mg/m2 BID day1-14

BActive comparator

Investigator's choice. If immunotherapy was used in the NAC setting, it was required to be used after NAC for up to 1 years.

Drugs: Apatinib, Camrelizumab, Capecitabine

Sites

1 site in 1 country

  • Sun Yat-sen Memorial HospitalGuangzhou, Guangodng, China